Anne Perdrix is an expert in Oncology at Centre Henri Becquerel (France). Anne Perdrix has authored 48 publications, the most recent in 2025, and is an investigator in 5 clinical trials. SLR score: 178 (community average: 125). How the SLR is computed.

LeadR Profile

Anne Perdrix Centre Henri Becquerel France
178 ScienceLeadR Reputation 178
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2009 - 2025

Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 48

Citations

Citations: 1 470 1st author: 8 Last author: 3 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.
PMID 40261555 — triple negative breast neoplasms, breast neoplasms, estradiol, cyclophosphamide, neoplasms, ovarian reserve, drug therapy, immunotherapy, aftercare, breast, therapeutics, carboplatin, plasma, chemotherapy
Breast Cancer Res Treat20250
Serum levels of the incretin-like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa-Ba-S study.
PMID 39350486 — diabetes mellitus, pilots, serum, obesity, incretins, meals, gastrectomy, obesity, morbid, diabetes mellitus, type 2
Diabetes Obes Metab20241
Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer.
PMID 39040450 — cells, circulating tumor dna, lymph nodes, carcinoma, squamous cell, uterine cervical neoplasms, brachytherapy, neoplasms, lymph, diagnosis, therapeutics, dna
Front Oncol20241
Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
PMID 37924026 — neoplasms, hormones, therapeutics, artificial intelligence, mutation, endometrial neoplasms
BMC Cancer20235
2022-RA-783-ESGO Clinical relevance of circulating<i>ESR1</i>mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
OpenAlex W4312826022 — neoplasms, hormones, therapeutics, mutation, carcinoma
Endometrial cancer20220

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 4
Phase 4 1

By status:

Completed 3
Recruiting 1
Unknown 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map